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Abstract 39 
Glucokinase (GK) is essential for glucose-stimulated insulin release from pancreatic β-40 
cell, serving as glucose sensor in humans. Inactivating or activating mutations of glucokinase 41 
lead to different forms of “Glucokinase Disease”, i.e. Monogenic Diabetes of Youth (GCK-42 
MDY), Permanent Neonatal Diabetes (inactivating mutations) and Congenital Hyperinsulinism, 43 
respectively. Here we present a novel GCK activating mutation (p.E442K) found in an infant 44 
with neonatal hypoglycaemia (1.5 mmol/l) and in two other family members suffering from 45 
recurrent hypoglycemic episodes in their childhood or adult life. In contrast to the severe 46 
clinical presentation in the index case, functional studies showed only a slight activation of the 47 
protein (relative activity index of 3.3). We also report on functional studies of two inactivating 48 
mutations of the GCK (p.E440G and p.S441W), contiguous to the activating one, that lead to 49 
GCK-MDY. Interestingly, adult family members carrying the GK pE440G mutation show a 50 
unusually “progressive” diabetic phenotype. 51 
Word count: 186?? 52 
53 
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INTRODUCTION 54 
Glucokinase enzyme (GK) has unique functional and structural properties for acting as 55 
the pancreatic -cell “glucose sensor”. GK plays thus a role in glucose-stimulated insulin 56 
release (GSIR) (1), and regulates the threshold for GSIR (GSIR-T) (1). The high control of GK 57 
on -cells function is best illustrated by the profound impact on GSIR-T of mutations of 58 
glucokinase gene (GCK). Indeed, GSIR-T in carriers of inactivating GCK mutations increases, 59 
leading to the mild fasting hyperglycemia in subjects with heterozygous mutations or to severe 60 
diabetes like in the case of individuals with homozygous or compound heterozygous mutations. 61 
The resulting clinical phenotype of partial glucokinase deficiency is GCK-Monogenic Diabetes 62 
of Youth (GCK-MDY), also known as Maturity Onset Diabetes of the Young 2 (MODY2) (2), 63 
while complete glucokinase deficiency leads to permanent, neonatal diabetes mellitus (GCK-64 
PNDM) (3,4). On the contrary, the GSIR-T in carriers of activating mutations of GCK 65 
decreases, causing hypoglycemia (GCK-HI) due to inappropriate insulin secretion when plasma 66 
glucose is below the normal GSIR-T, featuring mild or severe forms of the disease (5-8). These 67 
different GK linked disorders of glucose metabolism (GCK-MDY, GCK-PNDM and GCK-HI) 68 
are the three different forms of “glucokinase disease”. 69 
“Glucokinase disease” can be caused by missense GCK mutations located anywhere in 70 
the primary sequence with no major “hot spots” defined (9,10). However GCK-HI mutations 71 
cluster in the small domain of GK protein, where the allosteric activator site is located (11)  72 
In this manuscript we present a novel GCK activating mutation that, in spite of 73 
presenting the lowest relative activity index (%AI) and the highest predicted GSIR-T of all 74 
naturally occurring GK activating mutations described so far, leads to severe neonatal 75 
hypoglycaemia (1.5 mmol/l). Furthermore, we also report functional studies of contiguous 76 
inactivating mutations in GCK that lead to the hyperglycaemic form of the “glucokinase 77 
disease” (GK-MDY). 78 
 79 
RESULTS 80 
Identification of missense mutations in the GCK gene  81 
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Family trees of the three patients carrying the GCK mutations studied in this report are 82 
depicted in figure 1. Denaturing gradient electrophoresis (DGGE) experiments showed 83 
abnormal patterns of PCR products of exon 10 of the GCK in all affected families’ members 84 
available for analysis. We identified three missense mutations in the heterozygous state. A novel 85 
mutation in codon 442, with lysine substituting for glutamic acid (p.E442K) in the proband of 86 
family GCK-HI-1 (subject III-2 in Fig. 1a), as well as in her affected brother and mother 87 
(subjects III-1 and II-1 in Fig. 1a). A single nucleotide change resulting in a tryptophan for 88 
serine substitution at codon 441 (p.S441W) in the proband of family FE-11 (subject III-1 in Fig. 89 
1b), in his younger brother, his mother and maternal grandmother. This mutation had been 90 
previously described in another Italian family (10). Finally, a novel mutation resulting in a 91 
substitution of glutamic acid by glycine at codon 440 (p.E440G) was found in the proband of 92 
family FI-10 (subject III-1 in Fig. 1c), in his younger brother, in his father and in a paternal 93 
uncle. None of the mutations were found in 100 healthy controls’ chromosomes. 94 
Metabolic features of families with GK diseases 95 
Family GCK-HI-RM-1 (E442K). The proband with hypoglycaemia (Subject III-2 in Fig. 1a) 96 
was born at the 41st week of gestation and presented at 1st day of life with plasma glucose (PG) 97 
of 1.5 mmol/L. Her birth weight was 2,840 g and the clinical examination unremarkable. Family 98 
history disclosed that the maternal grand father, the mother as well as the eldest brother 99 
presented with recurrent, symptomatic “hypoglycemic-like” episodes characterized by cold 100 
sweating, pallor, fatigue, hunger, and tachycardia; in addtion, the mother and the brother of the 101 
index case showed fasting plasma glucose of 2.2-3.0 mmol/l in several occasions. At the age of 102 
3 weeks (weight: 4,200 g) the proband was referrred to the Metabolic Unit of Bambino Gesù 103 
Pediatric Hospital for further investigation. At that time her plasma glucose ranged between 1.9 104 
and 4.3 mmol/L. She  had normal plasma values of ammonia, lactate, triglycerides (122 mg/dl) 105 
and total cholesterol (130 mg/dl). The urine excretion of -ketoglutarate, another marker of HI 106 
due to gain-of-function mutations of glutamate dehydrogenase gene (GLUD1) (12), was normal, 107 
as well as blood acylcarnitines, aminoacids, and serum transferrin IEF. Abdominal and brain 108 
ultrasonography were also normal. Following i.m. glucagon (1 mg.), plasma glucose (PG) rose 109 
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from 2.2 to 6.0 mmol/L; simultaneous baseline evaluation of plasma cortisol (23 g/dl), IGF1 110 
(237 ng/ml) and ACTH (35 pg/ml) were all normal. These clinical investigations combined 111 
excluded some causes of hypoglycemia. Low dose diazoxide therapy (2 mg/kg/d) was started in 112 
the proband which normalized blood glucose and was continued for 3 months. The patient, now 113 
6 years old and on diet therapy only, did not suffer of any other symptomatic hypoglycemia; in 114 
contrast the patient’s elder brother experienced in the same time interval two unexplained 115 
syncopal episodes. 116 
Family FE-11 (S441W). All the affected members of this family (Fig. 1b) presented 117 
impaired fasting glucose (IFG) (6.5-6.9 mmol/l), and all were treated only with diet. The oral 118 
glucose tolerance test (OGTT) carried out in the proband (Fig. 1b, subject III-1) showed IGT 119 
and low plasma insulin at 30’ (18 U/ml with corresponding plasma glucose of 10 mmol/l) 120 
(Table 1), a result which is typically found in GCK-MDY patients. 121 
Family FI-10 (E440G). The proband and his younger brother presented impaired fasting 122 
glucose (IFG) (6.1 and 5.8 mmol/l, respectively) (Fig. 1c, subjects III-1 and III-2). Intravenous 123 
glucose tolerance test (IVGTT)-derived first-phase insulin response (FPIR) of children carrying 124 
the p.E440G mutation showed unexpectedly high figures of 300 and 241 U/ml. These values 125 
respectively exceed the 97th (260.7 U/ml) and the 90th (223.7 U/ml) centile of normal Italian 126 
children of corresponding pubertal status (13). This high FPIR was observed again in both 127 
brothers when the IVGTTs were repeated two years later (308 and 215 U/ml, respectively) 128 
(Table 1). In addiiton, adult family members carrying the mutation showed a diebetic 129 
phenotype, not typical of GCK-MDY, with proband’s father presenting high fasting plasma 130 
glucose (10.4 mmol/l) and a paternal uncle treated with oral hypoglycemic agents; unfortunately 131 
two other paternal uncles, one treated with OHA and another with insulin were not available for 132 
genetic analysis (Fig. 1). 133 
Kinetic analysis of recombinant wild type and mutant glucokinase. 134 
Kinetic properties of WT and mutant GK are shown in Table 2. Mutation GK-E442K 135 
showed a higher affinity for glucose (S0.5= 4.43 mmol/l) than GK-WT and a relative activity 136 
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index (%AI) which was over 3 times higher (Table 2), indicating that K442 is an activating 137 
mutation. On the contrary, mutations GK-E440G and GK-S441W showed a lower affinity for 138 
glucose, (S0.5 = 10.85 and 15.89 mmol/l, respectively), as compared to GK-WT. The lowest  139 
affinity for the second substrate MgATP2-, catalytical activity and cooperativity index (Hill 140 
number - nH) were found in mutation GK-S441W (Table 2). The %AI of GK- E440G and GK-141 
S441W were almost 60% and 90% lower than GK-WT. Consequently, the calculated GSIR-T of 142 
MDY-causing mutations GK-E440G and GK-S441W was higher than GK-WT (5.82 and 6.63 143 
mmol/l vs. 5 mmol/l respectively), while calculated GSIR-T of the activating mutation GK-144 
E442K was lower (4.14 mmol/l) than GK-WT (Fig. 2). 145 
Prediction of structural effects of naturally occurring glucokinase mutations 146 
We introduced the mutated residues into the closed active and super-open inactive GKB 147 
(Glucokinase Beta cell-specific) structure models described by Kamata et al (14) and then 148 
compared mutated GK-G440, GK-W441 and GK K442 with GK-WT. In Kamata’s model the 149 
side chain of Glu 442 (E442) is exposed to the solvent in both closed and super-open 150 
conformations. The mutant Lys residue in GK-HI-causing K442 would also be exposed to the 151 
solvent in both conformations (Fig. 3a). However, the positive charge of the side chain of the 152 
Lys 442 residue may interact with the negative charge of Glu 216 residue (E216), stabilizing the 153 
closed conformation. In addition, in the super-open conformation (Fig. 3a), the side chain of 154 
Lys 442 would be closer to Ala 454 residue (A454), destabilizing the super-open conformation. 155 
As a result, the structure of K442 enzyme would favor the closed, active conformation, and 156 
would consequently lead to higher glucose affinity. 157 
The change of Glu 440 residue (E440) by Gly residue (G440) (Fig. 3b) would 158 
destabilize the structure of the protein, since Gly residues are prone to modify the conformation 159 
of a particular structure. This interpretation would explain the observed reduction in glucose and 160 
MgATP2- affinity. In the case of the S441W mutation (Fig. 3c, W441), the new bulkier 161 
tryptophane residue would be projected toward the inside of the protein, destabilizing it because 162 
of its interaction with the α5 helix. This would cause a dramatic reduction in glucose affinity, as 163 
observed in in vitro experiments.  164 
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 165 
DISCUSSION 166 
In this report we present a novel activating GCK mutation (p.E442K) in a newborn with 167 
severe neonatal hypoglycemia. She is now 6 years old, in good general condition and treated 168 
with diet therapy only. Her older brother and mother, also bearing the same GCK mutation, did 169 
not present hypoglycemia in the neonatal period but repeated episodes of symptomatic 170 
hypoglycemia later in life. Functional studies of mutated protein showed an enzyme with almost 171 
a two-fold increase in glucose affinity compared to wild type GK. The E442 residue is located 172 
in a loop between 13 and 13 domains of GK. According to Kamata’s model (14), this loop 173 
plays an important role in the conformational change of the GK from the super-open to the 174 
closed active conformation of the enzyme. Although E442 does not participate directly in the 175 
binding to the allosteric activator (compound A in Kamata’s model) (14), the K442 mutation 176 
favours the transition to the closed conformation of the enzyme, leading to increased glucose 177 
affinity (Fig. 3a). The structural analysis along with the calculated %AI and GSIR-T (3.3 and 178 
4.14 mmol/l, respectively) obtained from the experimental data, indicate that the activation of 179 
GK caused by the E442K mutation is the cause of hypoglycaemia in the proband and in other 180 
members of the family carrying the mutation (Figure 1a). 181 
This mutation is a good example of the discrepancy one may find between the severity 182 
of the clinical phenotype at presentation and the data resulting from the functional analysis“in 183 
vitro” of the mutated enzyme. Indeed, the results of the kinetic analysis showed that the 184 
mutation E442K presents the lowest %AI as well as the highest GSIR-T of all naturally 185 
occurring GCK activating mutations described to date (11,15). This is in line with the relatively 186 
mild symptoms of hypoglycemia showed in affected members in childhood and adult life, but in 187 
contrast with the severe clinical onset presented by the proband. We can only speculate that the 188 
proband could have some transient immaturity of glucoregulatory pathways which contributed 189 
to lower her plasma glucose levels. However, we do not believe that this may be ascribed to the 190 
relatively low birth weight of the proband, whcih was in line with that reported in other patients 191 
with activating GCK mutations born from affected mothers (16). 192 
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We also described two inactivating GCK mutations (p.E440G, p.S441W) contiguous to 193 
the activating p.E442K. Patients carrying the mutation p.S441W present a phenotype highly 194 
characteristic of GCK-MDY patients, i.e. IFG combined with impaired glucose tolerance (IGT) 195 
with low values at tests evaluating (early) insulin release (17). In contrast, the two young and 196 
lean brothers carrying the mutation p.E440G showed high plasma insulin levels at 30’ of OGTT 197 
and in two independent IVGTT tests (Table 1). Alike the family previously reported with GCK-198 
MDY (mutation p.L184P) (18), we also observed some metabolic heterogeneity within the 199 
different E440G carriers of family FI-10 (Fig. 1). As a matter of fact, though functional and 200 
structural studies of GK-E440G (Table 2) fully explain the basic metabolic features of the 201 
proband and his brother, they are not sufficient to clarify the severe diabetic phenotype observed 202 
in adult family members carrying the mutation. Thus, the co-existence of other unknown genes 203 
implicated in glucose metabolism or unrecognized environmental factors should be considered 204 
in this kindred. 205 
 206 
MATERIAL and METHODS 207 
Subjects 208 
The proband with hypoglycemia (Subject III-2 in Fig. 1a) was referred to the Metabolic 209 
Unit of Bambino Gesù Children’s Hospital for diagnostic workup. Routine laboratory exams 210 
were all normal with the exception of insulin, which was inappropriately high (12 U/ml) for 211 
the corresponding plasma glucose. Family history disclosed that her elder brother and mother 212 
(subjects III-1 and II-1 in Fig. 1a) suffered repeated episodes of symptomatic hypoglycemia and 213 
the maternal grandfather (deceased, not tested) had “hypoglycemia-like” symptoms (i.e. 214 
sweatiness, headache, hunger and weakness). 215 
The diabetic probands studied in this report were identified during the course of an Italian 216 
nation-wide project aimed at selecting patients with monogenic diabetes (MD) (subjects III-1 in 217 
Fig. 1b and 1c) out of subjects referred to pediatric diabetes clinics for incidental hyperglycemia 218 
(10,19). 219 
Metabolic studies 220 
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Probands of families with (GCK-MDY) (subjects III-1 in Fig. 1b and 1c) underwent two 221 
tests as part of the protocol for studying subjects with incidental hyperglycemia: a standard 222 
OGTT with serum insulin determinations and an IVGTT. IVGTT was performed injecting 0.5 g 223 
of glucose per kg/body weight. Blood samples were taken at -15, 0, and 1, 3, 5, 10 minutes after 224 
the glucose injection for plasma insulin determination. FPIR was calculated as the sum of 225 
insulin immunoreactivity at minute 1 and 3 and the result compared to those obtained in normal 226 
Italian children according to their pubertal stage (13). Insulin assay was not centralized. 227 
However other IVGTT tests performed in the same center of family FI-10, on probands with 228 
mutations in the GCK always elicited low FPIR (see Table 1). All tests were approved by the 229 
local institutional ethics committee and a written informed consent was obtained from the 230 
parents of the probands. 231 
Molecular genetic studies 232 
Genomic DNA was extracted from peripheral lymphocytes. The complete coding sequence of 233 
the GCK was amplified by the polymerase chain reaction (PCR) and analysed by denaturing 234 
gradient electrophoresis (DGGE) as previously described (10). In the proband clinically defined 235 
as having hyperinsulinemic hypoglycemia and his relatives, screening of GCK gene was 236 
performed first, based on the autosomal-dominant mode of inheritance of hypoglycaemia (5, 237 
11). We excluded the possibility of mutations of the glutamate dehydrogenase gene (GDH) 238 
because of the normal plasma ammonia concentrations (20). The PCR products showing 239 
abnormal electrophoretic pattern were subjected to direct sequencing by an ABI DNA 240 
sequencing apparatus 373A (Perkin Elmer Applied Bio Systems, Foster City, CA). Mutations 241 
were confirmed in all affected family members available for analysis. 242 
Site-directed mutagenesis 243 
Mutations p.E440G, p.S441W, p.E442K on GCK were introduced into the wild type 244 
human pancreatic GCK using the Quick Change site-directed mutagenesis kit from Stratagene 245 
(La Jolla, CA), (oligonucleotides sequences available upon request). Plasmid pUC-GlkB was 246 
used as a template in the PCR reactions. All plasmids were sequenced to confirm that only the 247 
desired mutation had been introduced. Mutated plasmids (pUC-GlkB-E440G, S441W and 248 
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E442K) were digested with EcoRI and SalI and the insert subcloned into plasmid pGEX-6P-1 249 
(Amersham Pharmacia), to allow its expression in Escherichia coli as a glutathionyl S-250 
transferase (GST) fusion protein. Purified recombinant GST-GK was routinely screened for 251 
purity by SDS-PAGE. 252 
Kinetic and structural analysis of the GK protein  253 
Studies of the kinetic properties of GK wild type (GK-WT) and GK-E440G, GK-S441W 254 
and GK-E442K in the presence of 2 mmol of dithiothreitol per liter of reaction mixture were 255 
performed spectrophotometrically as described previously (21). At least three different 256 
preparations of GK-WT and GK-mutants were made and analysed. We used non-linear kinetics 257 
according to the Hill equation to determine the affinity of the enzyme for glucose, and the Hill 258 
coefficient that characterizes the sigmoidal glucose dependency of GK. In order to measure the 259 
glucose phosphorylation capacity of the enzyme we used the relative activity index, which was 260 
calculated according to the formula previously reported (11). The structural analysis of the 261 
activating mutation was carried out using the crystal structure of human GK (14). 262 
Mathematical modelling  263 
We used a minimal mathematical model (1,11,21) to assess the impact of GK mutations 264 
on GSIR. We determined the impact of blood glucose levels on GK expression for both wild 265 
type and mutated alleles by using the expression coefficient for either allele: e = (SnH x 2)/(SnH + 266 
S0.5nH), where S refers to the glucose level at threshold, nH is the Hill coefficient for 267 
cooperativeness with glucose, the numerical value of 2 indicates that half-maximal induction is 268 
achieved at glucose S0.5, and S0.5 refers to the concentration of glucose needed to achieve the 269 
half-maximal rate of phosphorylation (1, 11). 270 
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LEGENDS TO FIGURES. 348 
 349 
Fig. 1 Family-trees of families GCK-HI-1, FE-11 and FI-10. Patients with no mutations 350 
detected in GCK are denoted as n/n; those carrying the mutations are denoted as n/m; nt= not 351 
tested. Individuals identified by symbols with vertical white lines have IFG. Individuals with 352 
symbols filled in black have diabetes. Individuals with horizontal black lines have 353 
hyperinsulinism and hypoglycemia. Current treatment is indicated below patients’ symbols. 354 
 355 
Fig. 2 Threshold for glucose stimulated insulin release (t-GSIR) as a function of the relative 356 
activity index of glucokinase protein wild type (GK-WT) and naturally occurring mutations 357 
GK-E440G, GK-S441W and GK-E442K.  358 
 359 
Fig. 3 Close-up of the structural model of the GK-E440, GK-S441, GK-E442 (wild type), GK-360 
E440G, GK-S441W (GCK-MDY naturally occurring mutation) and GK-E442K (HI mutation). 361 
The key 5 and 13 helixes of glucokinase are indicated in the left structures of Panel a, 362 
(super-open conformation of glucokinase) (14) and Panels b, c (closed conformation) (14). An 363 
enlargement of the region of interest (dotted square) is shown in each panel. Mutated residues 364 
are shown in red. The interacting residues are in green, cyan and magenta. Crystal coordinates 365 
from the closed active (1V4S) and super-open inactive (1V4T) conformation of GlkB (14) were 366 
visualized using the Pymol Molecular Graphics System version 0.97 (Delano Scientific LLC). 367 
368 
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Table 1: Results of the metabolic studies performed in the probands with GCK-MDY.
(9); The results of this probamd presented in this table have been previously reported in Massa et al. Diabetologia 44:898-905. n.a.; not 
available.
IVGTT OGTT
Family/mutation AGE BMI FPIR FPG IRI/bas. IRI/30 min. PG/30 min. IRI/120 min. PG/120 min.
(years) (Kg/m 2 )  U/ml) (mmol/L)  U/ml)  U/ml) (mmol/L) U/ml) (mmol/L)
FI-10/E440G
Subject III-1 
1997 10 17.5 308 6.1 13.9 180 10 50 7
1999 12 310
Subject III-2 
1997 8 17.2 241 5.8 7 70 9.5 11.1 5.1
1999 10 215
FE-11/S441W
Subject III-1 10 n.a n.a 6.7 5 18 10 20 7.9
MI-34/S441W
Proband (9) 9 16.2 96 7.6 13 n.a. 12.8 n.a. 8.2
The following FPIR values have been obtained in probands with GCK mutation who underwent IVGTT in the same Center of
family FI-10: proband FI-2, mutation S383fsdelC1=37 (<1st centile; ref 18); proband FI-22, mutation Y108H=54 (=1st centile); 
proband FI-14, mutation L276P=56 (<3rd centile); proband FI-18, mutation F150Y=80 (<25th centile); proband FI-4, mutation
N231fsdelA=92 (=25th).
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 392 
 393 
394 
S0.5 nH ATPKm Kcat Relative Activity Index
(mmol/l) (unitless) (mmol/l) (sec
-1 ) (%AI)
WT 7.97±0.31    1
E440G 10.85±0.68    0.41
S441W 15.89±2.49    0.11
E442K 4.43±0.17    3.33
Table 2: Functional characteristics of the recombinants glucokinase proteins wild type (GK-WT), and the naturally 
occurring mutations GK-E440G, GK-S441W and GK-E442K. Data are means ± SE from three separate enzyme
preparations.
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